Table of Contents Author Guidelines Submit a Manuscript
Dermatology Research and Practice
Volume 2015 (2015), Article ID 145409, 7 pages
http://dx.doi.org/10.1155/2015/145409
Research Article

Decreased Circulating T Regulatory Cells in Egyptian Patients with Nonsegmental Vitiligo: Correlation with Disease Activity

1Faculty of Medicine, Dermatology and Venereology Department, Tanta University Hospitals, El Geish Street, Tanta 31111, Egypt
2Faculty of Medicine, Clinical Pathology Department, Tanta University Hospitals, El Geish Street, Tanta 31111, Egypt

Received 10 September 2015; Revised 28 November 2015; Accepted 30 November 2015

Academic Editor: Elizabeth Helen Kemp

Copyright © 2015 Doaa Salah Hegab and Mohamed Attia Saad Attia. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. Alikhan, L. M. Felsten, M. Daly, and V. Petronic-Rosic, “Vitiligo: a comprehensive overview Part I. Introduction, epidemiology, quality of life, diagnosis, differential diagnosis, associations, histopathology, etiology, and work-up,” Journal of the American Academy of Dermatology, vol. 65, no. 3, pp. 473–491, 2011. View at Publisher · View at Google Scholar
  2. G. F. Mohammed, A. H. Gomaa, and M. S. Al-Dhubaibi, “Highlights in pathogenesis of vitiligo,” World Journal of Clinical Cases, vol. 3, no. 3, pp. 221–230, 2015. View at Publisher · View at Google Scholar
  3. K. Ongenae, N. Van Geel, and J.-M. Naeyaert, “Evidence for an autoimmune pathogenesis of vitiligo,” Pigment Cell Research, vol. 16, no. 2, pp. 90–100, 2003. View at Publisher · View at Google Scholar · View at Scopus
  4. J. Kasznicki and J. Drzewoski, “A case of autoimmune urticaria accompanying autoimmune polyglandular syndrome type III associated with Hashimoto's disease, type 1 diabetes mellitus, and vitiligo,” Endokrynologia Polska, vol. 65, no. 4, pp. 320–323, 2014. View at Publisher · View at Google Scholar · View at Scopus
  5. N. Oiso, T. Suzuki, K. Fukai, I. Katayama, and A. Kawada, “Nonsegmental vitiligo and autoimmune mechanism,” Dermatology Research and Practice, vol. 2011, Article ID 518090, 7 pages, 2011. View at Publisher · View at Google Scholar
  6. Í. Caramalho, H. Nunes-Cabaço, R. B. Foxall, and A. E. Sousa, “Regulatory T-cell development in the human thymus,” Frontiers in Immunology, vol. 6, article 395, 2015. View at Google Scholar
  7. K. E. Birch, M. Vukmanovic-Stejic, J. R. Reed, A. N. Akbar, and M. H. A. Rustin, “The immunomodulatory effects of regulatory T cells: implications for immune regulation in the skin,” British Journal of Dermatology, vol. 152, no. 3, pp. 409–417, 2005. View at Publisher · View at Google Scholar · View at Scopus
  8. S. Sakaguchi, “Naturally arising CD4+ regulatory T cells for immunologic self-tolerance and negative control of immune responses,” Annual Review of Immunology, vol. 22, pp. 531–562, 2004. View at Publisher · View at Google Scholar · View at Scopus
  9. B. Singh, J. A. Schwartz, C. Sandrock, S. M. Bellemore, and E. Nikoopour, “Modulation of autoimmune diseases by interleukin (IL)-17 producing regulatory T helper (Th17) cells,” Indian Journal of Medical Research, vol. 138, no. 5, pp. 591–594, 2013. View at Google Scholar · View at Scopus
  10. Q. Tang and J. A. Bluestone, “The Foxp3+ regulatory T cell: a jack of all trades, master of regulation,” Nature Immunology, vol. 9, no. 3, pp. 239–244, 2008. View at Publisher · View at Google Scholar · View at Scopus
  11. R. D'Amelio, C. Frati, A. Fattorossi, and F. Aiuti, “Peripheral T-cell subset imbalance in patients with vitiligo and in their apparently healthy first-degree relatives,” Annals of Allergy, vol. 65, no. 2, pp. 143–145, 1990. View at Google Scholar · View at Scopus
  12. I. Hamzavi, H. Jain, D. McLean, J. Shapiro, H. Zeng, and H. Lui, “Parametric modeling of narrowband UV-B phototherapy for vitiligo using a novel quantitative tool: the Vitiligo Area Scoring Index,” Archives of Dermatology, vol. 140, no. 6, pp. 677–683, 2004. View at Publisher · View at Google Scholar · View at Scopus
  13. T. Kawakami and T. Hashimoto, “Disease severity indexes and treatment evaluation criteria in vitiligo,” Dermatology Research and Practice, vol. 2011, Article ID 750342, 3 pages, 2011. View at Publisher · View at Google Scholar · View at Scopus
  14. E. M. Shevach, “CD4+CD25+ suppressor T cells: more questions than answers,” Nature Reviews Immunology, vol. 2, no. 6, pp. 389–400, 2002. View at Publisher · View at Google Scholar
  15. F. Annunziato, L. Cosmi, F. Liotta et al., “Phenotype, localization, and mechanism of suppression of CD4+CD25+ human thymocytes,” The Journal of Experimental Medicine, vol. 196, no. 3, pp. 379–387, 2002. View at Publisher · View at Google Scholar
  16. S. Hori, T. Nomura, and S. Sakaguchi, “Control of regulatory T cell development by the transcription factor Foxp3,” Science, vol. 299, no. 5609, pp. 1057–1061, 2003. View at Publisher · View at Google Scholar
  17. A. Richetta, S. D'Epiro, M. Salvi et al., “Serum levels of functional T-regs in vitiligo: our experience and mini-review of the literature,” European Journal of Dermatology, vol. 23, no. 2, pp. 154–159, 2013. View at Publisher · View at Google Scholar · View at Scopus
  18. M. Dwivedi, N. C. Laddha, P. Arora, Y. S. Marfatia, and R. Begum, “Decreased regulatory T-cells and CD4+/CD8+ ratio correlate with disease onset and progression in patients with generalized vitiligo,” Pigment Cell & Melanoma Research, vol. 26, no. 4, pp. 586–591, 2013. View at Publisher · View at Google Scholar
  19. Y. Lili, W. Yi, Y. Ji, S. Yue, S. Weimin, and L. Ming, “Global activation of CD8+ cytotoxic T lymphocytes correlates with an impairment in regulatory T cells in patients with generalized vitiligo,” PLoS ONE, vol. 7, no. 5, Article ID e37513, 2012. View at Publisher · View at Google Scholar · View at Scopus
  20. M. Ben Ahmed, I. Zaraa, R. Rekik et al., “Functional defects of peripheral regulatory T lymphocytes in patients with progressive vitiligo,” Pigment Cell and Melanoma Research, vol. 25, no. 1, pp. 99–109, 2012. View at Publisher · View at Google Scholar · View at Scopus
  21. J. Klarquist, C. J. Denman, C. Hernandez et al., “Reduced skin homing by functional Treg in vitiligo,” Pigment Cell and Melanoma Research, vol. 23, no. 2, pp. 276–286, 2010. View at Publisher · View at Google Scholar · View at Scopus
  22. F. Mahmoud, H. Abul, D. Haines, C. Al-Saleh, M. Khajeji, and K. Whaley, “Decreased total numbers of peripheral blood lymphocytes with elevated percentages of CD4+CD45RO+ and CD4+CD25+ of T-helper cells in non-segmental vitiligo,” The Journal of Dermatology, vol. 29, no. 2, pp. 68–73, 2002. View at Google Scholar
  23. M. A. Elela, R. A. Hegazy, M. M. Fawzy, L. A. Rashed, and H. Rasheed, “Interleukin 17, interleukin 22 and FoxP3 expression in tissue and serum of non-segmental vitiligo: a case- controlled study on eighty-four patients,” European Journal of Dermatology, vol. 23, no. 3, pp. 350–355, 2013. View at Publisher · View at Google Scholar · View at Scopus
  24. N. H. Moftah, R. A. H. El-Barbary, M. A. Ismail, and N. A. M. Ali, “Effect of narrow band-ultraviolet B on CD4+  CD25high FoxP3+T-lymphocytes in the peripheral blood of vitiligo patients,” Photodermatology Photoimmunology and Photomedicine, vol. 30, no. 5, pp. 254–261, 2014. View at Publisher · View at Google Scholar · View at Scopus
  25. G. Roncador, P. J. Brown, L. Maestre et al., “Analysis of FOXP3 protein expression in human CD4+CD25+ regulatory T cells at the single-cell level,” European Journal of Immunology, vol. 35, no. 6, pp. 1681–1691, 2005. View at Publisher · View at Google Scholar · View at Scopus
  26. H. Yagi, T. Nomura, K. Nakamura et al., “Crucial role of FOXP3 in the development and function of human CD25+CD4+ regulatory T cells,” International Immunology, vol. 16, no. 11, pp. 1643–1656, 2004. View at Publisher · View at Google Scholar
  27. L. J. Chi, H. B. Wang, and W. Z. Wang, “Impairment of circulating CD4+CD25+ regulatory T cells in patients with chronic inflammatory demyelinating polyradiculoneuropathy,” Journal of the Peripheral Nervous System, vol. 13, no. 1, pp. 54–63, 2008. View at Publisher · View at Google Scholar
  28. M. A. Kriegel, T. Lohmann, C. Gabler, N. Blank, J. R. Kalden, and H.-M. Lorenz, “Defective suppressor function of human CD4+CD25+ regulatory T cells in autoimmune polyglandular syndrome type II,” Journal of Experimental Medicine, vol. 199, no. 9, pp. 1285–1291, 2004. View at Publisher · View at Google Scholar · View at Scopus
  29. A. C. Abreu, G. G. Duarte, J. Y. Miranda, D. G. Ramos, C. G. Ramos, and M. G. Ramos, “Immunological parameters associated with vitiligo treatments: a literature review based on clinical studies,” Autoimmune Diseases, vol. 2015, Article ID 196537, 5 pages, 2015. View at Publisher · View at Google Scholar
  30. M. K. Tembhre, V. K. Sharma, A. Sharma, P. Chattopadhyay, and S. Gupta, “T helper and regulatory T cell cytokine profile in active, stable and narrow band ultraviolet B treated generalized vitiligo,” Clinica Chimica Acta, vol. 424, pp. 27–32, 2013. View at Publisher · View at Google Scholar · View at Scopus
  31. R. A. Hegazy, M. M. Fawzy, H. I. Gawdat, N. Samir, and L. A. Rashed, “T helper 17 and Tregs: a novel proposed mechanism for NB-UVB in vitiligo,” Experimental Dermatology, vol. 23, no. 4, pp. 283–286, 2014. View at Publisher · View at Google Scholar · View at Scopus
  32. J. M. Eby, H. Kang, S. T. Tully et al., “CCL22 to activate treg migration and suppress depigmentation in vitiligo,” Journal of Investigative Dermatology, vol. 135, no. 6, pp. 1574–1580, 2015. View at Publisher · View at Google Scholar
  33. J. A. Bluestone, E. Trotta, and D. Xu, “The therapeutic potential of regulatory T cells for the treatment of autoimmune disease,” Expert Opinion on Therapeutic Targets, vol. 19, no. 8, pp. 1091–1103, 2015. View at Publisher · View at Google Scholar